Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo and Cambridge, MA – April 22, 2015 -- Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today...
MSD K.K. (Head office: Tokyo; President: Tony Alvarez) and Astellas Pharma Inc. (Head office: Tokyo; President: Yoshihiko Hatanaka) signed a memorandum of understanding regarding co-development...
TOKYO and HOUSTON – April 3, 2015 – Astellas Pharma Inc. (TSE: 4503) and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and...
SAN FRANCISCO, CA and TOKYO, JAPAN – April 2, 2015 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 STRIVE trial...
Follow us
